The Proline Rich Domain of P53 is Dispensable for MGMT-dependent DNA Repair and Cell Survival Following Alkylation Damage

Overview

Journal Cell Death Differ

Specialty Cell Biology

Date 2017 Jul 29

PMID 28753207

Citations 5

Authors

Katherine Baran

Mao Yang

Christopher P Dillon

Leona L Samson

Douglas R Green

Affiliations

Soon will be listed here.

Abstract

In addition to promoting cell death and senescence, p53 also has important cellular survival functions. A mutant p53, lacking a proline-rich domain (p53), that is deficient in controlling both cell death and cell cycle arrest, was employed to determine the biological means by which p53 mediates survival upon DNA damage. While p53 and p53 cells were equally resistant to many DNA damaging agents, p53 cells showed an exquisite resistance to high doses of the alkylating agent Diazald (N-Methyl-N-(p-tolylsulfonyl)nitrosamide), as compared to cells completely deficient for p53 function. We determined that p53 was capable of transcribing the repair gene, MGMT (O6-methylguanine-DNA methyltransferase) after irradiation or alkylation damage, resulting in DNA repair and cell survival. Consistent with these observations, p53 mice show enhanced survival after IR relative to p53 mice. Suppression or deletion of MGMT expression in p53 cells inhibited DNA repair and survival after alkylation damage, whereas MGMT overexpression in p53-deficient cells facilitated DNA repair and conferred survival advantage. This study shows that when cell death and cell cycle arrest pathways are inhibited, p53 can still mediate MGMT-dependent repair, to promote cell survival upon DNA damage.

Citing Articles

Temozolomide-Promoted MGMT Transcription Contributes to Chemoresistance by Activating the ERK Signalling Pathway in Malignant Melanoma.

Deng M, Ren B, Zhao J, Guo X, Yang Y, Shi H J Cell Mol Med. 2025; 29(3):e70380.

PMID: 39873425 PMC: 11773391. DOI: 10.1111/jcmm.70380.

Elucidating the clonal relationship of esophageal second primary tumors in patients with laryngeal squamous cell carcinoma.

Wan M, Yang X, He L, Meng H Infect Agent Cancer. 2023; 18(1):75.

PMID: 38017473 PMC: 10685475. DOI: 10.1186/s13027-023-00558-z.

Integration of stool microbiota, proteome and amino acid profiles to discriminate patients with adenomas and colorectal cancer.

Bosch S, Acharjee A, Quraishi M, Bijnsdorp I, Rojas P, Bakkali A Gut Microbes. 2022; 14(1):2139979.

PMID: 36369736 PMC: 9662191. DOI: 10.1080/19490976.2022.2139979.

p53: From Fundamental Biology to Clinical Applications in Cancer.

Capuozzo M, Santorsola M, Bocchetti M, Perri F, Cascella M, Granata V Biology (Basel). 2022; 11(9).

PMID: 36138802 PMC: 9495382. DOI: 10.3390/biology11091325.

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.

Wu W, Klockow J, Zhang M, Lafortune F, Chang E, Jin L Pharmacol Res. 2021; 171:105780.

PMID: 34302977 PMC: 8384724. DOI: 10.1016/j.phrs.2021.105780.

References

Chipuk J, Maurer U, Green D, Schuler M . Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell. 2003; 4(5):371-81. DOI: 10.1016/s1535-6108(03)00272-1. View

Bernstein C, Bernstein H, Payne C, Garewal H . DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res. 2002; 511(2):145-78. DOI: 10.1016/s1383-5742(02)00009-1. View

Goth-Goldstein R . Inability of Chinese hamster ovary cells to excise O6-alkylguanine. Cancer Res. 1980; 40(7):2623-4. View

Iwakuma T, Sakumi K, Nakatsuru Y, Kawate H, Igarashi H, Shiraishi A . High incidence of nitrosamine-induced tumorigenesis in mice lacking DNA repair methyltransferase. Carcinogenesis. 1997; 18(8):1631-5. DOI: 10.1093/carcin/18.8.1631. View

Wulf G, Liou Y, Ryo A, Lee S, Lu K . Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem. 2002; 277(50):47976-9. DOI: 10.1074/jbc.C200538200. View

Campbell H, Mehta R, Neumann A, Rubio C, Baird M, Slatter T . Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD). Oncogene. 2012; 32(7):827-36. DOI: 10.1038/onc.2012.102. View

Nagasaka T, Goel A, Notohara K, Takahata T, Sasamoto H, Uchida T . Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer. 2008; 122(11):2429-36. PMC: 2851179. DOI: 10.1002/ijc.23398. View

Jeggo P, Pearl L, Carr A . DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer. 2015; 16(1):35-42. DOI: 10.1038/nrc.2015.4. View

Grombacher T, Eichhorn U, Kaina B . p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene. 1998; 17(7):845-51. DOI: 10.1038/sj.onc.1202000. View

10.

Dornan D, Shimizu H, Burch L, Smith A, Hupp T . The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol Cell Biol. 2003; 23(23):8846-61. PMC: 262654. DOI: 10.1128/MCB.23.23.8846-8861.2003. View

11.

Edwards S, Hananeia L, Eccles M, Zhang Y, Braithwaite A . The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions. Oncogene. 2003; 22(29):4517-23. DOI: 10.1038/sj.onc.1206726. View

12.

Kaina B . Mechanisms and consequences of methylating agent-induced SCEs and chromosomal aberrations: a long road traveled and still a far way to go. Cytogenet Genome Res. 2004; 104(1-4):77-86. DOI: 10.1159/000077469. View

13.

Wiewrodt D, Nagel G, Dreimuller N, Hundsberger T, Perneczky A, Kaina B . MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int J Cancer. 2007; 122(6):1391-9. DOI: 10.1002/ijc.23219. View

14.

Becker K, Dosch J, Gregel C, Martin B, Kaina B . Targeted expression of human O(6)-methylguanine-DNA methyltransferase (MGMT) in transgenic mice protects against tumor initiation in two-stage skin carcinogenesis. Cancer Res. 1996; 56(14):3244-9. View

15.

Toledo F, Krummel K, Lee C, Liu C, Rodewald L, Tang M . A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell. 2006; 9(4):273-85. DOI: 10.1016/j.ccr.2006.03.014. View

16.

RAFFERTY J, Clarke A, Sellappan D, Koref M, Frayling I, Margison G . Induction of murine O6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent. Oncogene. 1996; 12(3):693-7. View

17.

Bieging K, Mello S, Attardi L . Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014; 14(5):359-70. PMC: 4049238. DOI: 10.1038/nrc3711. View

18.

Reese J, Allay E, Gerson S . Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice. Oncogene. 2001; 20(38):5258-63. DOI: 10.1038/sj.onc.1204700. View

19.

Esteller M, Risques R, Toyota M, Capella G, Moreno V, Peinado M . Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001; 61(12):4689-92. View

20.

Jacks T, Remington L, Williams B, Schmitt E, Halachmi S, Bronson R . Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994; 4(1):1-7. DOI: 10.1016/s0960-9822(00)00002-6. View